Yan Tong
Research Subjects
Yan Tong has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Haiyan Zuo
Institute of Acupuncture and Meridian, Anhui University of Chinese Medicine, Hefei, China
1 shared publication - Jie Zhou
The Third School of Clinical Medicine, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Hangzhou, Zhejiang, China
1 shared publication - Kun Wang
College of Traditional Chinese Medicine
1 shared publication - Meiqi Zhou
Key Laboratory of Xin’an Medicine, the Ministry of Education and Key Laboratory of Molecular Biology (Brain diseases), Anhui University of Chinese Medicine, Hefei, China
1 shared publication - Qiaoyu Qu
Anhui Maternal and Child Health Hospital
1 shared publication - Shengbing Wu
Anhui Province Key Laboratory of Meridian Viscera Correlationship, Anhui University of Chinese Medicine, Hefei, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 1984706
Electroacupuncture Ameliorates Acute Myocardial Ischemic Injury and Long QT Interval in Mice through the α1A‐Adrenergic Receptor: Electrophysiological, Morphological, and Molecular Evidence
Acute myocardial ischemia (AMI) is a condition caused by a decrease in blood flow to the heart that can sometimes predispose to acquired long QT syndrome (LQTS), thereby resulting in sudden cardiac death. Recent evidence indicates that electroacupuncture (EA) can alleviate MI injury, but its specific mechanism remains unclear. This study was aimed at investigating the efficacy of EA, which utilizes α1A‐adrenergic receptors (α1A‐AR) in alleviating MI injury as well as the resulting LQTS. The AMI model was established by ligating the left anterior descending arteries (LAD) of both the wild‐type and α1A gene‐knockout mice and treating them with EA for three consecutive days. A PowerLab 16 physiological recorder was used to collect the electrocardiogram (ECG) while the serum creatine kinase isoenzymes (CK‐MB), lactate dehydrogenase (LDH), and norepinephrine (NE) levels in myocardial tissue were determined by using the enzyme‐linked immunosorbent assay (ELISA) kit. Moreover, TTC staining was used to observe the myocardial ischemic area, while H&E and TUNEL staining determined the pathological morphology of the myocardium. Quantitative real‐time PCR (qRT‐PCR) was used to detect the α1A mRNA, and Western blot was used to detect the specific proteins, such as α1A, cleaved caspase‐3, Gq, PLC, p‐PKCα, and p‐hERG. Our results showed that EA could effectively reduce elevated ST‐segment, shorten the extended QT interval, and reduce the serum myocardial enzyme content and the degree of pathological injury in wild mice with MI. EA can also decrease the expression of α1A‐AR, PLC, p‐PKCα, and NE content in myocardial tissues of wild mice, while those of p‐hERG increased in ischemic myocardial tissue. These findings suggested that α1A‐AR is involved in the development of MI as well as LQTS. Additionally, EA treatment improves the cardiac function and ischemic long QT interval and plays an important role in reducing the hERG inhibition through the α1A‐AR‐mediated Gq/PLC/PKCα pathway and myocardial apoptosis. Hence, it is suggested that α1A‐AR might become a potential target for EA in treating AMI treatment of myocardial ischemia injury and acquired long QT intervals caused by MI.
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 1984706
Open AccessElectroacupuncture Ameliorates Acute Myocardial Ischemic Injury and Long QT Interval in Mice through the α1A‐Adrenergic Receptor: Electrophysiological, Morphological, and Molecular Evidence
Acute myocardial ischemia (AMI) is a condition caused by a decrease in blood flow to the heart that can sometimes predispose to acquired long QT syndrome (LQTS), thereby resulting in sudden cardiac death. Recent evidence indicates that electroacupuncture (EA) can alleviate MI injury, but its specific mechanism remains unclear. This study was aimed at investigating the efficacy of EA, which utilizes α1A‐adrenergic receptors (α1A‐AR) in alleviating MI injury as well as the resulting LQTS. The AMI model was established by ligating the left anterior descending arteries (LAD) of both the wild‐type and α1A gene‐knockout mice and treating them with EA for three consecutive days. A PowerLab 16 physiological recorder was used to collect the electrocardiogram (ECG) while the serum creatine kinase isoenzymes (CK‐MB), lactate dehydrogenase (LDH), and norepinephrine (NE) levels in myocardial tissue were determined by using the enzyme‐linked immunosorbent assay (ELISA) kit. Moreover, TTC staining was used to observe the myocardial ischemic area, while H&E and TUNEL staining determined the pathological morphology of the myocardium. Quantitative real‐time PCR (qRT‐PCR) was used to detect the α1A mRNA, and Western blot was used to detect the specific proteins, such as α1A, cleaved caspase‐3, Gq, PLC, p‐PKCα, and p‐hERG. Our results showed that EA could effectively reduce elevated ST‐segment, shorten the extended QT interval, and reduce the serum myocardial enzyme content and the degree of pathological injury in wild mice with MI. EA can also decrease the expression of α1A‐AR, PLC, p‐PKCα, and NE content in myocardial tissues of wild mice, while those of p‐hERG increased in ischemic myocardial tissue. These findings suggested that α1A‐AR is involved in the development of MI as well as LQTS. Additionally, EA treatment improves the cardiac function and ischemic long QT interval and plays an important role in reducing the hERG inhibition through the α1A‐AR‐mediated Gq/PLC/PKCα pathway and myocardial apoptosis. Hence, it is suggested that α1A‐AR might become a potential target for EA in treating AMI treatment of myocardial ischemia injury and acquired long QT intervals caused by MI.